As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of the industry’s iPSC development efforts. In this webinar transcript, which was hosted on Cell & Gene Therapy Insights in March 2024, industry experts delve into the critical aspects of reshaping the future landscape of iPSC-based therapies.
This technical application poster, originally showcased at ISCT 2024, shares data demonstrating that SOLUPORE® technology, a non-viral system and novel transfection platform, efficiently produces single and multi-gene edited induced pluripotent stem cells (iPSCs). iPSCs hold therapeutic potential due to their ability to differentiate into various cell types and this application is further enhanced by gene
Induced pluripotent stem cell (iPSC)-based therapies offer advantages in their potential to address clinical applicability and scalable manufacturing to meet patient demand. As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of development efforts. Despite these noteworthy strides, there are still many existing dilemmas to address for sustained progress and commercial viability. Hear from experts as they delve into critical aspects to reshape the landscape of iPSC-based therapies.
iPSC-Based Therapy Dilemmas Explored: Overcoming Hurdles for Future Success Read More »
DiscGenics is a biopharmaceutical company that develops regenerative cell-based…
Establishing a bank of 100 patient-derived iPSC lines and isogenic controls…
The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT) Read More »
An optimized 14-day manufacturing workflow developed in < 12 months...
Process Development for Scaled-Up hESC/hiPSC Manufacturing Read More »
Translation of a cell therapy protocol from bench-scale to bioreactor…
